Evans Medical Plc manufactures, markets, and distributes health products.
Price History & Performance
|Historical stock prices|
|Current Share Price||₦0.50|
|52 Week High||₦0|
|52 Week Low||₦0|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||0%|
|3 Year Change||0%|
|5 Year Change||0%|
|Change since IPO||-51.11%|
Recent News & Updates
|EVANSMED||NG Pharmaceuticals||NG Market|
Return vs Industry: EVANSMED underperformed the NG Pharmaceuticals industry which returned 35.1% over the past year.
Return vs Market: EVANSMED underperformed the NG Market which returned 40.2% over the past year.
Stable Share Price: EVANSMED is less volatile than 75% of NG stocks over the past 3 months, typically moving +/- 0% a week.
Volatility Over Time: EVANSMED's weekly volatility (0%) has been stable over the past year.
About the Company
Evans Medical Plc manufactures, markets, and distributes health products. The company operates in the Over the Counter and Prescriptive segments. Its products include anti-malarials, ant-infectives, anti-asthamatics, anti-histaminics, analgesics, anti-ulcerants, anti-hypertensives, anti-diabetics, cold and cough preparations, erectile dysfunctions, energy supplements, herbal products, haematinics blood forming preparations, prostagladins, vitamins and minerals, topical preparations, and pharyngeals.
Evans Medical Fundamentals Summary
|EVANSMED fundamental statistics|
Is EVANSMED overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EVANSMED income statement (TTM)|
|Cost of Revenue||₦1.96b|
Last Reported Earnings
Dec 31, 2014
Next Earnings Date
|Earnings per share (EPS)||0|
|Net Profit Margin||0.00%|
How did EVANSMED perform over the long term?See historical performance and comparison
Is Evans Medical undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Evans Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Evans Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Evans Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Evans Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Evans Medical performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Evans Medical has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
How is Evans Medical's financial position?
In this section we usually analyse Evans Medical's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Evans Medical has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
What is Evans Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVANSMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVANSMED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVANSMED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVANSMED's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: EVANSMED is not paying a notable dividend for the NG market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVANSMED's dividend in 3 years as they are not forecast to pay a notable one for the NG market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Evans Medical has no CEO, or we have no data on them.
Experienced Board: EVANSMED's board of directors are considered experienced (8.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Evans Medical Plc's employee growth, exchange listings and data sources
- Name: Evans Medical Plc
- Ticker: EVANSMED
- Exchange: NGSE
- Founded: 1954
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₦366.174m
- Shares outstanding: 732.35m
Number of Employees
- Evans Medical Plc
- Plot 6, Abimbola Way
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 15:20|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.